Efficacy and Safety of Upadacitinib versus Dupilumab Treatment for Moderate-to-Severe Atopic Dermatitis in Four Body Regions: Analysis from the Heads Up Study

By sjmartinez • February 4, 2025

Thyssen JP, Rosmarin D, Costanzo A, Warren R, Chu CY, Chovatiya R, Ladizinski B, Hu X, Liu Y, Calimlim B, Nduaka C, Vigna N, Armstrong A. Efficacy and Safety of Upadacitinib versus Dupilumab Treatment for Moderate-to-Severe Atopic Dermatitis in Four Body Regions: Analysis from the Heads Up Study. Dermatology. 2025;241(1):10-18. doi: 10.1159/000542275. Epub 2024 Oct 30. PMID: 39476813.

Tags: atopic dermatitis, Body region, Dermatology, Dupilumab, EASI, eczema, Publications, Upadacitinib

Patient-Reported Outcomes by Baseline Body Surface Area Involvement Among Individuals Initiating Biologic Therapy: Results from the CorEvitas Psoriasis Registry

Armstrong AW, Feldman SR, Fitzgerald T, Alkousakis T, Sima A, Li A, Kang HJ, Main SI, Khattri S, Stein Gold L. Patient-Reported Outcomes by Baseline[...]

Biologic Mechanisms Underlying the Heterogeneous Response to Tight Glycemic Control among Differentially Inflamed Patients in the HALF-PINT Trial

Zinter MS, Taylor CS, Markovic D, Pellegrini M, Wong K, Balliu B, Gala KP, Asaro LA, Nadkarni VM, McQuillen PS, Vangala SS, Sinha P, Matthay[...]

Cutaneous manifestation of metastatic papillary thyroid carcinoma

Peng D, Dong E, Martinez D, Kang Y, Wong D, Holland V. Cutaneous manifestation of metastatic papillary thyroid carcinoma. JAAD Case Rep. 2025 Apr 11;60:129-131.[...]